Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma.
Johnson DC et al. Nat Commun. 2016 Jan 8;7:10290. doi: 10.1038/ncomms10290.
A novel small molecule agent displays potent anti-myeloma activity by inhibiting the JAK2-STAT3 signaling pathway.
Zhang Z et al. Oncotarget. 2016 Jan 22. doi: 10.18632/oncotarget.6974. [Epub ahead of print].
Myxoma Virus Induces Ligand Independent Extrinsic Apoptosis in Human Myeloma Cells.
Bartee MY et al. Clin Lymphoma Myeloma Leuk. 2015 Dec 23. pii: S2152-2650(15)01432-9. doi: 10.1016/j.clml.2015.12.005. [Epub ahead of print].
Inhibition of Transforming Growth Factor β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma.
Lu A et al. Am J Pathol. 2016 Jan 19. pii: S0002-9440(15)00653-7. doi: 10.1016/j.ajpath.2015.11.003. [Epub ahead of print].
A DNA-binding Molecule Targeting the Adaptive Hypoxic Response in Multiple Myeloma has Potent Anti-tumor Activity.
Mysore VS et al. Mol Cancer Res. 2016 Jan 22. pii: molcanres.0361.2015. [Epub ahead of print].
Cross-talk between two antioxidants, thioredoxin reductase and heme oxygenase-1, and therapeutic implications for multiple myeloma.
Raninga PV et al. Redox Biol. 2016 Jan 11;8:175-185. doi: 10.1016/j.redox.2016.01.007. [Epub ahead of print].
A CD2 high-expressing stress resistant human plasmacytoid dendritic cell subset.
Bryant C et al. Immunol Cell Biol. 2016 Jan 21. doi: 10.1038/icb.2015.116. [Epub ahead of print].
Inhibition of glucose transporter 1 induces apoptosis and sensitizes multiple myeloma cells to conventional chemotherapeutic agents.
Matsumoto T et al. Leuk Res. 2015 Dec 23. pii: S0145-2126(15)30566-X. doi: 10.1016/j.leukres.2015.12.008. [Epub ahead of print].
Association of MDR1 single-nucleotide polymorphisms and haplotype variants with multiple myeloma in Chinese Jiangsu Han population.
Yin G et al. Tumour Biol. 2016 Jan 20. [Epub ahead of print].
Phagocyte Function Decreases after High-Dose Treatment with Melphalan and Autologous Stem Cell Transplantation in Patients with Multiple Myeloma.
Wichert S et al. Exp Hematol. 2016 Jan 13. pii: S0301-472X(16)00006-0. doi: 10.1016/j.exphem.2016.01.002. [Epub ahead of print].
Ex Vivo Evaluation of the Effect of Regulatory T Cells (Treg) on the Anti-Tumor Activity of Bortezomib in Multiple Myeloma.
Ercetin AP et al. Exp Hematol. 2016 Jan 13. pii: S0301-472X(16)00003-5. doi: 10.1016/j.exphem.2015.05.019. [Epub ahead of print].
miRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc.
Saha MN et al. Oncotarget. 2016 Jan 11. doi: 10.18632/oncotarget.6880. [Epub ahead of print].
miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth.
Fulciniti M et al. Blood Cancer J. 2016 Jan 15;6:e380. doi: 10.1038/bcj.2015.106.
MMSET is dynamically regulated during cell-cycle progression and promotes normal DNA replication.
Evans DL et al. Cell Cycle. 2016 Jan 2;15(1):95-105. doi: 10.1080/15384101.2015.1121323.
Myeloma impairs mature osteoblast function but causes early expansion of osteo-progenitors: temporal changes in bone physiology and gene expression in the KMS12BM model.
Kassen D et al. Br J Haematol. 2016 Jan;172(1):64-79. doi: 10.1111/bjh.13790. Epub 2015 Nov 2.
Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1; A Potential Therapeutic Strategy for MyelomaBone Disease.
Eda H et al. J Bone Miner Res. 2016 Jan 13. doi: 10.1002/jbmr.2789. [Epub ahead of print].
RANK-RANKL interactions are involved in cell adhesion-mediated drug resistance in multiple myeloma cell lines.
Tsubaki M et al. Tumour Biol. 2016 Jan 14. [Epub ahead of print].
Kinetic analysis and molecular modelling of the inhibition mechanism of roneparstat (SST0001) on human heparanase.
Pala D et al. Glycobiology. 2016 Jan 13. pii: cww003. [Epub ahead of print].
Plasma Thrombin Generation and Sensitivity to Activated Protein C Among Patients With Myeloma and Monoclonal Gammopathy of Undetermined Significance.
Crowley MP et al. Clin Appl Thromb Hemost. 2016 Jan 11. pii: 1076029615625825. [Epub ahead of print].
Mevalonate Pathway and Human Cancers.
Zahra Bathaie S et al. Curr Mol Pharmacol. 2016 Jan 12. [Epub ahead of print].
Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.
Agarwal P et al. Oncotarget. 2016 Jan 7. doi: 10.18632/oncotarget.6843. [Epub ahead of print].
Nuclear TRAF3 is a negative regulator of CREB in B cells.
Mambetsariev N et al. Proc Natl Acad Sci U S A. 2016 Jan 26;113(4):1032-7. doi: 10.1073/pnas.1514586113. Epub 2016 Jan 11.
Bone marrow infiltration by multiple myeloma causes anemia by reversible disruption of erythropoiesis.
Bouchnita A et al. Am J Hematol. 2016 Jan 9. doi: 10.1002/ajh.24291. [Epub ahead of print].
TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myelomathrough NF-кβ inhibition.
Raninga PV et al. Cell Cycle. 2016 Jan 8:0. [Epub ahead of print].
Impact of Polymorphic Variations of Gemcitabine Metabolism, DNA Damage Repair, and Drug Resistance Genes on the Effect of High-Dose Chemotherapy for Relapsed or Refractory Lymphoid Malignancies.
Shinozuka K et al. Biol Blood Marrow Transplant. 2015 Dec 29. pii: S1083-8791(15)01917-5. doi: 10.1016/j.bbmt.2015.12.022. [Epub ahead of print].
Ex vivo and in vivo evaluation of over-expressed VLA-4 in multiple myeloma using LLP2A imaging agents.
Soodgupta D et al. J Nucl Med. 2016 Jan 7. pii: jnumed.115.164624. [Epub ahead of print].
Correlation of Mast Cell Density With Angiogenic Cytokines in Patients With Active Multiple Myeloma.
Vyzoukaki R et al. Clin Ther. 2015 Dec 28. pii: S0149-2918(15)01318-1. doi: 10.1016/j.clinthera.2015.11.022. [Epub ahead of print].
Wogonin inhibits multiple myeloma-stimulated angiogenesis via c-Myc/VHL/HIF-1α signaling axis.
Fu R et al. Oncotarget. 2015 Dec 30. doi: 10.18632/oncotarget.6796. [Epub ahead of print].
Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma.
Conery AR et al. Elife. 2016 Jan 5;5. pii: e10483. doi: 10.7554/eLife.10483. [Epub ahead of print].
Differential expression of alkaline phosphatase gene in proliferating primary lymphocytes and malignant lymphoid cell lines.
Latheef SA et al. Immunol Lett. 2015 Dec 28;170:37-41. doi: 10.1016/j.imlet.2015.12.008. [Epub ahead of print].
Cilengitide restrains the osteoclast-like bone resorbing activity of myeloma plasma cells.
Tucci M et al. Br J Haematol. 2016 Jan 5. doi: 10.1111/bjh.13922. [Epub ahead of print].
The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival.
Ohguchi H et al. Nat Commun. 2016 Jan 5;7:10258. doi: 10.1038/ncomms10258.
Thromboxane A2 Receptor Inhibition Suppresses Multiple Myeloma Cell Proliferation by Inducing P38/JNK MAP Kinase Mediated-G2/M Progression Delay and Cell Apoptosis.
Liu Q et al. J Biol Chem. 2016 Jan 2. pii: jbc.M115.683052. [Epub ahead of print].
A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition.
Alagpulinsa DA et al. Mol Cancer Ther. 2015 Dec 30. [Epub ahead of print].
Cell adhesion downregulates the expression of Homer1b/c and contributes to drug resistance in multiple myeloma cells.
Tang J et al. Oncol Rep. 2015 Dec 29. doi: 10.3892/or.2015.4532. [Epub ahead of print].
Genistein inhibits the proliferation of human multiple myeloma cells through suppression of nuclear factor‑κB and upregulation of microRNA‑29b.
Xie J et al. Mol Med Rep. 2015 Dec 30. doi: 10.3892/mmr.2015.4740. [Epub ahead of print].
Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells.
Lub S et al. Oncotarget. 2015 Dec 26. doi: 10.18632/oncotarget.6768. [Epub ahead of print].
Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells.
Meißner T et al. BMC Med Genomics. 2015 Dec 30;8(1):85. doi: 10.1186/s12920-015-0161-6.
Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myelomatumors.
Mitra AK et al. Leukemia. 2015 Dec 29. doi: 10.1038/leu.2015.361. [Epub ahead of print].
Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax.
Matulis SM et al. Leukemia. 2015 Dec 28. doi: 10.1038/leu.2015.350. [Epub ahead of print].